Patents Assigned to Vericel Corporation
  • Patent number: 11857576
    Abstract: The present disclosure provides compositions and methods for repairing cartilage defects.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: January 2, 2024
    Assignee: Vericel Corporation
    Inventors: Ross A. Tubo, Xing Zhao
  • Patent number: 11857170
    Abstract: The present disclosures describe devices and methods to repair cartilage defects using arthroscopic surgical methods. The disclosed devices include a cannula assembly including a cannula body, a dam seal sub-assembly disposed proximally from the cannula body, and an obturator inserted coaxially through both the cannula body and the dam seal sub-assembly; an articulated arthroscopic cutting tool; a ring curette; a square curette; a rake curette; a matrix shuttle delivery device for delivering a cell-seeded support matrix including chondrocytes; and an applicator tool.
    Type: Grant
    Filed: March 3, 2023
    Date of Patent: January 2, 2024
    Assignee: Vericel Corporation
    Inventors: Felix Ernesto Robles Toth, Robert Bruce Mackinnon, III, Lester H. Fehr
  • Patent number: 10011811
    Abstract: Described is a device comprising an anchor, a tray including a well adapted to receive the anchor, and a cover adapted to engage the tray and cover the well. The device may be used to form a membrane-cell matrix having a substantially uniform distribution of the cells on the membrane in at least two dimensions.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: July 3, 2018
    Assignee: Vericel Corporation
    Inventors: Yongzhong Wang, Christopher Kelly, Stephen Rapko, Frank Quinno, Barbara Seymour
  • Patent number: 9415071
    Abstract: The present invention provides a fluid exchange cell culture technique and tissue repair cells (TRCs) made by these methods, as well as methods using these cells. The method includes a new wash step which increases the tissue repair properties of the TRCs of the invention. This wash step allows for the production of TRC populations with greater tissue repair and anti-inflammatory capabilities. Embodiments of the present invention include a post-culture process for cultured cells that preferably includes the steps of: a wash process for removing unwanted residual culture components, a volume reduction process, and a harvesting process to remove cultured cells. Preferably, all these steps are performed within a aseptically closed cell culture chamber by implementing a separation method that minimizes mechanical disruption of the cells and is simple to automate. The harvested cells may then be concentrated to a final volume for the intended use.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: August 16, 2016
    Assignee: Vericel Corporation
    Inventors: Brian Hampson, Kristin Goltry, Douglas M. Smith, Jonathan A. Rowley, Naia Venturi